MARKET WIRESimply Wall St • 22h ago
Alkermes (NasdaqGS:ALKS) Stock Forecast & Analyst PredictionsSimply Wall St report covering Jazz Pharmaceuticals plc (Ireland) (JAZZ) market action, institutional positioning, and fundamental catalysts.
Why JAZZ Stock slipped -0.71% Today — RQD Quant Desk Flash
$214.44 -0.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $213.76
Jazz Pharmaceuticals plc (Ireland) (JAZZ) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $14.02B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on JAZZ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is JAZZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Jazz Pharmaceuticals plc (Ireland) (NASDAQ: JAZZ) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $214.44 (-0.71% 1D, market cap $14.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, JAZZ ranks #268 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does JAZZ compare to BBIO and SMMT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAZZ carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -4.7%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $14.60B) and SMMT (Summit Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.82B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for JAZZ?
▼
Per JAZZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001232524), Jazz Pharmaceuticals plc (Ireland) generated $4.27B in revenue (+4.9% YoY), -$356.1M in net income, and $1.30B in free cash flow against $11.66B in total assets and $4.33B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $213.75 (-0.32%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 30.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JAZZ)Realized 20D OHLCV Swing Band: ±6.6%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY JAZZ SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (27% of score)
SEC Form 4 / 13F Thermometer: 65% Net Buy • Cannibal Buyback (-1.52% YoY Shares)
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 30.4% FCF Margin ($1.30B FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)
Macro rate sensitivity & RSI-14 (48.5) create a -13 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$209.65+1.1% Next Q
41
Q2 (-2Q)Grade D$211.97-3.3% Next Q
44
Q3 (-1Q)Grade D$205.06+4.6% Next Q
46
CurrentGrade D$214.44-5.4% Hist 90D α
49
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a JAZZ Turnaround Squeeze
While JAZZ currently carries a cautious 49/100 (D) rating due to Macro Regime Fit (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($229.21) and Max Pain ($225.16) forces dealer call-delta covering toward $279.70.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $JAZZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JAZZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JAZZ Stock slipped -0.71% Today — RQD Quant Desk Flash
Jazz Pharmaceuticals plc (Ireland) (JAZZ) slipped -0.71% to $214.44, trading at 62% of its 52-week range ($128.8 – $266.38). Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 62% of its 52-week range ($128.8 – $266.38) with RSI-14 at 48.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.6% around $214.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $1.3B annual free cash flow.
Live JAZZ Headlines & Catalysts
MARKET WIREYahoo • 1d ago
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at the upcoming 2026 Society for Neuro-Oncology (SNO) Annual Meeting, tak
CATALYSTBenzinga • 1d ago
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face TestApple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott International, Entergy,
MARKET WIREYahoo • 2d ago
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earningsBiopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect.
CATALYSTYahoo • 3d ago
3 Biotech Stocks With Upside Of Up To 80%Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, hig
MARKET WIREYahoo • 4d ago
With Setara, the team behind Actio opens its second actThe fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
MARKET WIREYahoo • 4d ago
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion IndicationsSAN DIEGO, October 30, 2026--Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90
CATALYSTBenzinga • 5d ago
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.
CATALYSTYahoo • 6d ago
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineJazz Pharmaceuticals' strategy is starting to pay dividends.
CATALYSTYahoo • 7d ago
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseUltragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JAZZ)
- ✓Walkthrough of JAZZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JAZZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.07%📐 HORIZONTAL RANGE
2026-11-03O $207.8H $216.0L $207.8C $214.4VOL 1.22M
RES: $292.9SUP: $200.2SMA50: $229.2SMA200: $217.3
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JAZZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
27.7%/yr Implied 5Y Growth
vs. +4.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on JAZZ today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JAZZ. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JAZZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JAZZ)
Health Care Rank #268 of 1015
⚔️ BBIO vs JAZZ Full Matrix →
1. Head-to-Head Health Care Peer Comparison (JAZZ vs. BBIO, SMMT, ASND, RDY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Jazz Pharmaceuticals plc (Ireland) (JAZZ) ranks #268 by composite RQD confidence (49/100, grade D) and #83 by equity capitalization ($14.02B). Within this direct 5-issuer industry benchmark cohort, ASND leads on earnings valuation at 32.8x trailing P/E, while ASND leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. ASND currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with JAZZ at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JAZZ
ACTIVE
Jazz Pharmaceuticals plc (Ireland) | D | 49/100 | — | — | -4.7% | -0.71% | $14.02B | Benchmark Subject |
| BBIO BridgeBio Pharma Inc. | E | 34/100 | — | 95.8% | -35.0% | +0.06% | $14.60B | /bbio-vs-jazz → |
| SMMT Summit Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -7.67% | $12.82B | /smmt-vs-jazz → |
| ASND Ascendis Pharma A/S Ordinary Share | C+ | 69/100 | 32.8x | — | 9.9% | -0.91% | $16.55B | /asnd-vs-jazz → |
| RDY Dr. Reddy's Laboratories Ltd | C | 64/100 | 32.8x | — | 9.9% | -0.28% | $11.83B | /rdy-vs-jazz → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001232524 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jazz Pharmaceuticals plc (Ireland) (JAZZ) reported GAAP revenue of $4.27B (+4.9% vs. FY2024 revenue of $4.07B , and +11.3% cumulative change since FY2023) , GAAP net income of -$356.1M, operating cash flow of $1.36B, and free cash flow of $1.30B (-4.5% YoY). On the balance sheet, JAZZ closed FY2025 with $11.66B in total assets against $4.33B in total debt (Altman Z-Score: 1.97, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.27B | -$356.1M | $1.36B | $1.30B | $11.66B | $4.33B |
| FY2024 (FY) | 2024-12-31 | $4.07B | $560.1M | $1.40B | $1.36B | $12.01B | $6.08B |
| FY2023 (FY) | 2023-12-31 | $3.83B | $414.8M | $1.09B | $919.5M | $7.42B | $1.74B |
3. JAZZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs JAZZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Jazz Pharmaceuticals plc (Ireland) (NASDAQ: JAZZ) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $214.44 (-0.71% 1D, market cap $14.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, JAZZ ranks #268 in composite RQD confidence.
How does JAZZ compare to BBIO and SMMT in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAZZ carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -4.7%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $14.60B) and SMMT (Summit Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.82B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for JAZZ?
Per JAZZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001232524), Jazz Pharmaceuticals plc (Ireland) generated $4.27B in revenue (+4.9% YoY), -$356.1M in net income, and $1.30B in free cash flow against $11.66B in total assets and $4.33B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is JAZZ trading relative to its 50-day, 200-day, and 52-week technical levels?
JAZZ last traded at $214.44 (-0.71% on volume of 1,043,980 shares), positioning the stock -6.44% below its 50-day simple moving average ($229.21) and -1.29% below its 200-day simple moving average ($217.25). Across its 52-week range of $128.80 to $266.38, JAZZ sits at the 62.2% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±6.6% ($200.29 to $228.59).
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ SEC XBRL & RQD VERIFIED
JAZZ — Jazz Pharmaceuticals plc (Ireland): What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Jazz Pharmaceuticals plc (Ireland) (JAZZ) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $214.44 (-0.71% 1D, market capitalization $14.02B).
- Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -4.7%, gross margin of —, operating margin of -10.1%, and free cash flow yield of 9.61%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (9/20): Incorporates a 1.09x equity beta, Altman Z-Score of 1.97, Piotroski F-Score of 7/9, and Debt/Equity of 1.00x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Trades under JAZZ on NASDAQ. It sits in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jazz Pharmaceuticals plc (Ireland) (JAZZ) reported $4.27B in annual revenue (up from $4.07B in FY2024, +4.9% YoY) and -$356.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.83B revenue, $414.8M net income) through FY2025, JAZZ scaled operating cash flow to $1.36B and free cash flow to $1.30B, backed by $11.66B in total assets against $4.33B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 9.61% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $128.80 – $266.38 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against -10.1% operating margins and a 1.09x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), JAZZ carries a macro regime beta of 1.09 and gross margin of —.
- Key Question #1: Can JAZZ sustain or expand its -10.1% operating margin and -4.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $4.27B and free cash flow of $1.30B, how will capital allocation balance growth reinvestment against $4.33B in total debt?
- Key Question #3: How sensitive is JAZZ's 36.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.09x)?
JAZZ Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Jazz Pharmaceuticals plc (Ireland) (JAZZ) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Simply Wall St • 22h ago
Alkermes (NasdaqGS:ALKS) Stock Forecast & Analyst Predictions Simply Wall St report covering Jazz Pharmaceuticals plc (Ireland) (JAZZ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 1d ago
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at the upcoming 2026 Society for Neuro-Oncology (SNO) Annual Meeting, tak
🟢 CATALYST Benzinga • 1d ago
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott International, Entergy,
🟡 MARKET WIRE Yahoo • 2d ago
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect.
🟢 CATALYST Yahoo • 3d ago
3 Biotech Stocks With Upside Of Up To 80% Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, hig
🟡 MARKET WIRE Yahoo • 4d ago
With Setara, the team behind Actio opens its second act The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
🟡 MARKET WIRE Yahoo • 4d ago
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications SAN DIEGO, October 30, 2026--Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90
🟢 CATALYST Benzinga • 5d ago
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300 JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
JAZZ Bull vs. Bear Conversation Board — What's Your Call at $214.44?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JAZZ 🐻 33% BEARISH CONVICTION
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH
🎯 Target: $259.18 (+20.0%)
📌 Pinned Debate Free cash flow of $1.30B in FY 2025 and a 9.61% FCF yield show the business still generates meaningful cash despite accounting losses
Long JAZZ at $215.98 targeting $259.18. Free cash flow of $1.30B in FY 2025 and a 9.61% FCF yield show the business still generates meaningful cash despite accounting losses.. Institutional whale score is 10/20 and the risk/reward vs. the $128.80 52-week low is skewed heavily in favor of bulls.
VolSurface_Trader 🐂 BULL
@SkepticalCFA Shorting a 10/20 institutional whale-flow stock at $215.98 is dangerous when funds are rotating into Health Care.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $172.78 (-20.0%)
Spot @ $215.98 Operating income swung to -$430.2M in FY 2025 with ROIC at -4.7%, while the RQD rating places the stock in a Sell category with weak in
Fading this rally in JAZZ at $215.98. Operating income swung to -$430.2M in FY 2025 with ROIC at -4.7%, while the RQD rating places the stock in a Sell category with weak institutional flow.. With a beta of 1.09 and the stock sitting at $215.98 (52-wk range $128.80–$266.38), the easy multiple expansion is already priced in.